Identification of allosteric binding sites for PI3K alpha oncogenic mutant specific inhibitor design.
Miller, M.S., Maheshwari, S., McRobb, F.M., Kinzler, K.W., Amzel, L.M., Vogelstein, B., Gabelli, S.B.(2017) Bioorg Med Chem 25: 1481-1486
- PubMed: 28129991 
- DOI: 10.1016/j.bmc.2017.01.012
- Primary Citation of Related Structures:  
5SW8, 5SWG, 5SWO, 5SWP, 5SWR, 5SWT, 5SX8, 5SX9, 5SXA, 5SXB, 5SXC, 5SXD, 5SXE, 5SXF, 5SXI, 5SXJ, 5SXK - PubMed Abstract: 
PIK3CA, the gene that encodes the catalytic subunit of phosphatidylinositol 3-kinase α (PI3Kα), is frequently mutated in breast and other types of cancer. A specific inhibitor that targets the mutant forms of PI3Kα could maximize treatment efficiency while minimizing side-effects ...